LB Pharmaceuticals Inc (LBRX) Current Ratio
- Current ratio · latest quarter: Value 15.08×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 15.08× | Current assets / current liabilities. $355.30M ÷ $23.56M ≈ 15.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 355.30M USD | Assets, Current |
| Current obligations | 23.56M USD | Liabilities, Current |
| Cash and equivalents | 283.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 44.68M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.49M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $355.30M | $23.56M | $283.11M | $44.68M | (m) | (m) | $3.49M | (m) | 15.08× |
| 2026-03-31 | $389.07M | $10.91M | $320.68M | $44.96M | (m) | (m) | $7.12M | (m) | 35.68× |
| 2025-12-31 | $308.43M | $7.44M | $250.17M | $45.04M | (m) | (m) | $2.13M | (m) | 41.44× |
| 2025-09-30 | $316.40M | $6.65M | $269.74M | $44.73M | (m) | (m) | $2.59M | (m) | 47.60× |
| 2024-12-31 | $28.88M | $8.11M | $22.98M | $5.02M | (m) | (m) | $2.32M | (m) | 3.56× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |